Pharmacological reversal of endothelin-1 mediated constriction of the spiral modiolar artery: a potential new treatment for sudden sensorineural hearing loss

Elias Q Scherer*1,2, Wolfgang Arnold2 and Philine Wangemann1

Address: 1Cell Physiology Laboratory, Dept. Anatomy & Physiology, Kansas State University, Manhattan, KS 66506, USA and 2Department of Otorhinolaryngology, Head and Neck Surgery, Technical University of Munich, Klinikum rechts der Isar, Ismaninger Str. 22, 81675 Munich, Germany

Email: Elias Q Scherer* - e.q.scherer@lrz.tum.de; Wolfgang Arnold - w.arnold@lrz.tum.de; Philine Wangemann - wange@vet.ksu.edu

* Corresponding author

Abstract

Background: Vasospasm of the spiral modiolar artery (SMA) may cause ischemic stroke of the inner ear. Endothelin-1 (ET-1) induces a strong, long-lasting constriction of the SMA by increasing contractile apparatus Ca2+ sensitivity via Rho-kinase. We therefore tested several Rho-kinase inhibitors and a cell-permeable analogue of cAMP (dbcAMP) for their ability to reverse ET-1-induced constriction and Ca2+-sensitization.

Methods: The present study employed SMA isolated from gerbil temporal bones. Ca2+ sensitivity was evaluated by correlating vascular diameter and smooth muscle cell [Ca2+]i, measured by fluo-4-microfluorometry and videomicroscopy.

Results: The Rho-kinase inhibitors Y-27632, fasudil, and hydroxy-fasudil reversed ET-1-induced vasoconstriction with an IC50 of 3, 15, and 111 µmol/L, respectively. DbcAMP stimulated a dose-dependent vasodilation (EC50 = 1 mmol/L) and a reduction of [Ca2+]i (EC50 = 0.3 µmol/L) of ET-1-preconstricted vessels (1 nmol/L). Fasudil and dbcAMP both reversed the ET-1-induced increase in Ca2+ sensitivity.

Conclusion: Rho-kinase inhibition and dbcAMP reversed ET-1-induced vasoconstriction and Ca2+-sensitization. Therefore, Rho-kinase inhibitors or cAMP modulators could possess promise as pharmacological tools for the treatment of ET-1-induced constriction, ischemic stroke and sudden hearing loss.

Background

The inner ear's blood supply depends solely on the spiral modiolar artery (SMA), a functional end artery. Vasospasm/constriction of the SMA can cause an ischemic stroke of the inner ear, leading to sudden sensorineural hearing loss (SSHL). Thus, investigating the mechanisms controlling the inner ear microcirculation is a prerequisite for the development of new strategies to treat SSHL.

Capillary blood flow is primarily regulated by the resistance of precapillary arteries. The vascular resistance is a function of the contractile status of the vascular smooth muscle cells (VSMCs). Constriction of VSMCs results from
an increase in intracellular $\text{Ca}^{2+}$ ($[\text{Ca}^{2+}]_i$) and/or by an increase in the $\text{Ca}^{2+}$ sensitivity of the contractile apparatus [1,2]. One key mechanism enhancing $\text{Ca}^{2+}$ sensitivity and thus vascular tone is Rho-kinase signalling, which results in inhibition of myosin light chain phosphatase [2,3]. Rho-kinase activation has been shown to cause vasospasm of coronary, cerebral and spiral modiolar arteries [4-9].

One of the strongest Rho-kinase activators described so far is the vasoconstrictor endothelin-1 (ET-1). The synthesis of ET-1 by endothelial cells is activated by physiological stimuli such as shear stress, insulin, thrombin and other vascular factors [10]. ET-1 and ET$_\alpha$ receptors play a fundamental role in the maintenance of basal vasomotor tone in resistance arteries [11]. The synthesis of ET-1 can be increased by hypoxia and elevated oxidized low-density lipoproteins [12,13] and has been implicated in the pathogenesis of a number of cerebrovascular disorders, including stroke, ischemia, and, in particular, cerebral vasospasm [14,15]. Thus, ET-1 possesses pathological potential in addition to its physiological functions. ET-1 is present in the SMA and induces strong, long-lasting constriction via ET$_\alpha$-receptor-mediated Rho-kinase activation [9,16,17]. Taken together ET-1 is likely an endogenous regulator of inner ear microvascular tone.

We have previously shown that CGRP is able to reverse ET-1-induced constrictions in the SMA via an increase in vascular smooth muscle cAMP [18]. CGRP is present in perivascular nerves of the SMA and therefore is a potential endogenous vasodilator of the SMA. We propose, therefore, that reversal of ET-1-induced constriction is not necessarily limited to inhibition of ET-1-related mechanisms (e.g., Rho-kinase signalling).

These findings provide a clinical perspective for a new treatment of SSHL, because both Rho-kinase signalling and cAMP can be targeted via pharmacological agents. Therefore, we assessed the potency of clinically relevant Rho-kinase inhibitors and a cell-permeable analogue cAMP (dbcAMP) in terms of reversing ET-1-induced constriction and $\text{Ca}^{2+}$-sensitization in the SMA.

**Methods**

**Drugs and solutions**

The physiologic salt solution (PSS) contained (in mmol/L) 150 NaCl, 3.6 KCl, 1.0 MgCl$_2$, 1.0 CaCl$_2$, 5.0 HEPES, and 5.0 glucose, pH 7.4. Extracellular $\text{Ca}^{2+}$ concentration ($[\text{Ca}^{2+}]_e$) was raised to 3 and 10 mmol/L by addition of CaCl$_2$. A maximal vasodilation was induced by the removal of extracellular $\text{Ca}^{2+}$. The nominally $\text{Ca}^{2+}$-free solution contained (in mmol/L) 150 NaCl, 3.6 KCl, 1.0 MgCl$_2$, 1.0 EGTA, 5.0 HEPES, and 5.0 glucose, pH = 7.4. Fluo-4-AM (Molecular Probes) was dissolved in anhydrous DMSO and stored in 1 mmol/L aliquots. Y-27632 was kindly provided by Welfide. Fasudil was obtained from Calbiochem. Fasudil (obtained from Tocris Cookson) was modified to hydroxyfasudil by Dr. Duy Hua, Dept of Chemistry, Kansas State University. All other chemicals were obtained from Sigma.

**Preparation of the spiral modiolar artery (SMA)**

Experiments were conducted on tissues isolated from gerbils under a protocol that was approved by the Institutional Animal Care and Use Committee at Kansas State University. Gerbils were anesthetized with sodium pentobarbital (100 mg/kg i.p.) and decapitated. Temporal bones were removed, opened and placed into a micro-dissection chamber containing PSS at 4°C. The SMA was isolated from the cochlea by micro-dissection as described previously [19]. Briefly, the cochlea was opened. The bone surrounding the modiolus was carefully removed and the SMA, which is only loosely attached to the eighth cranial nerve, was isolated. Care was taken to not stretch the artery.

**Simultaneous measurement of vascular diameter and $[\text{Ca}^{2+}]_i$**

The simultaneous measurement of vascular diameter and $[\text{Ca}^{2+}]_i$ has been described previously [17]. Briefly, the smooth muscle cells of vessel segments were loaded with the $\text{Ca}^{2+}$ indicator dye fluo-4 by incubation in PSS containing 5 µmol/L fluo-4-AM for 35 min at 37°C. After loading, vessel segments were washed with PSS and maintained at 4°C for 20 minutes prior to experimentation at 37°C. Vessel segments were transferred into a bath chamber mounted on the stage of an inverted microscope (Nikon). Fluorescence emitted by fluo-4 (518–542 nm) in response to excitation at 488 nm (Photon Technology International) was detected by a photon counter (Photon Technology International). For measurements of the vascular diameter, the vessel was illuminated at 605–615 nm and the transmission image was recorded with a chilled CCD camera (Hamamatsu). The outer vascular diameter was measured by two video edge detectors (Crescent). Fluorescence and calibrated diameter signals were digitized and recorded simultaneously (Photon Technology International).

**Experimental protocols**

Experiments were started 20 min after loading with fluo-4. Vessel segments were superfused at a rate of 9 ml/min with PSS. This flow rate corresponds to an exchange rate of 2 bath chambers volumes/sec, given the bath chamber volume of 75 µl. Upon start of the superfusion, the unpressurized artery develops a spontaneous vascular tone that is sensitive to removal of extracellular $\text{Ca}^{2+}$ and inhibition of L-type $\text{Ca}^{2+}$ channels with nanomolar concentrations of nifedipine [19]. The viability of each vessel
**Figure 1**

**Rho-kinase inhibitors reverse ET-1-induced constriction.**

**A)** Effect of 10 nmol/L endothelin-1 (ET-1) on the cytosolic Ca$^{2+}$ concentration ([Ca$^{2+}$]$_i$) and the vascular diameter of the spiral modiolar artery. Note that ET-1 caused a transient increase in [Ca$^{2+}$]$_i$ and a sustained vasoconstriction and increase in vasomotion. This constriction outlasted the stimulation with ET-1. Increasing extracellular Ca$^{2+}$ concentration ([Ca$^{2+}$]$_{ex}$) to 10 mmol/L ("Ca") induced an increase in [Ca$^{2+}$]$_i$ with parallel vasoconstriction. This increase of the [Ca$^{2+}$]$_{ex}$ from 1 to 10 mmol/L ("Ca") served as a control experiment. Measurements of [Ca$^{2+}$]$_i$ were normalized to the value obtained prior to the admission of ET-1 (value at time 'x' was set to 1).

**B)** In the presence of 10 nmol/L ET-1, increasing concentrations of fasudil (1–100 µmol/L) induce dose-dependent relaxation. [Ca$^{2+}$]$_i$ values were normalized, with the baseline value prior to application of ET-1 designated as 1.0 (denoted as "x").

**C)** Dose-response curves for Y-27632-, fasudil- and hydroxy-fasudil-induced reversal of ET-1 (10 nmol/L) -mediated vasoconstriction. **D)** ET-1 stimulated a significant increase in VSMC contractile apparatus Ca$^{2+}$ sensitivity. **E)** Fasudil completely reversed the ET-1-induced Ca$^{2+}$ sensitization.
was assessed by its constrictor response to 10 mmol/L 
[Ca²⁺]o. The [Ca²⁺]i was monitored as fluorescence inten-
sity and was normalized to the basal fluorescent emission 
prior to the beginning of each experiment. The fluores-
cence and diameter values taken for statistical analysis 
represent averages of the [Ca²⁺]-fluorescence and the vas-
cular diameter over 30 sec beginning 30 sec after the onset 
of stimulation. We carefully validated the [Ca²⁺]-meas-
urements with the non-ratiometric Ca²⁺-dye fluo-4 by (i) 
excluding artefacts due to vessel diameter changes (evalu-
ated by [Ca²⁺]i-versus ET-1 dose-response curves), (ii) 
excluding significant differences in the magnitude of 
[Ca²⁺],-changes between preparations, and (iii) assessing 
the same optimal dye-loading conditions in each exper-
iment [9,17].

Affinity constants (KDB) and concentrations that cause a 

half-maximal inhibition (IC₅₀) were determined in cumu-
lative experiments and averaged after logarithmic trans-
formation (pKDB and pIC₅₀) as previously described [17].

The Ca²⁺ sensitivity of the contractile apparatus was deter-
mined by a correlation of [Ca²⁺], and the vascular diam-
ter as described previously [9]. Changes in [Ca²⁺], were 
induced by changes in [Ca²⁺]o. Stepwise increases in 
[Ca²⁺]o from 0 to 1, 3 and 10 mmol/L caused increases in 
[Ca²⁺], and decreases in the vascular diameter. Correla-
tions were found to be linear (r > 0.95) within the mea-
sured range (the relation between calcium concentration 
and tension gets sigmoidal if the [Ca²⁺]o and thus the 
[Ca²⁺], is further increased [9]). Slopes were quantified in 
the arbitrary unit µm/Ca²⁺, where µm represent the 
change in the vascular diameter and Ca²⁺ represents the 
normalized change in the cytosolic Ca²⁺ concentration. Linear slopes were obtained to compare the Ca²⁺ sensi-
tivity within paired experiments. In each vessel segment, the 
Ca²⁺ sensitivity was assessed under control and under 
experimental conditions.

Experiments of dbcAMP induced dilations were bracketed 
by Ca²⁺ free manoeuvres that were performed to induce a 
maximal vasodilation and reduce the [Ca²⁺], to a minimal 
level. Vascular diameter or fluorescence intensity in the 
absence of Ca²⁺ was considered as baseline. The magni-
tude of the vascular tone or fluorescence intensity was 
determined as the difference between the recorded value 
and the baseline value. Measurements were averaged over 
a period of 1 min to average vasomotion. DbcAMP-
induced effects were normalized to the magnitude of the 
vascular tone or fluorescence intensity during 1 min 
immediately prior to the application of dbcAMP.

Statistical analysis
All results are expressed as average ± SEM of n experiments 
with n representing the number of vessel segments. The 
significance of changes in the vascular diameter and of 
changes in the Ca²⁺ sensitivity were determined using 
Student’s paired t-test. Differences were considered to be sig-
nificant at error probabilities less than 0.05 (P < 0.05).

Results
This report is based on recordings of 50 vessels from 34 
animals. The average vascular diameter was 65 ± 1 µm.

**ET-1-induced constriction is reversed via Rho-kinase 
inhibitors**

ET-1 (10 nmol/L) induced a transient increase in [Ca²⁺], 
a strong and long-lasting vasoconstriction and a robust 
increase in the vasomotion of the gerbil spiral modiolar 
artery (Fig. 1A). The [Ca²⁺], returned to almost resting lev-
els after the transient increase, while the constriction was 
maintained. The ET-1-induced vasoconstriction was not 
readily reversible upon removal of ET-1 from the per-
fuse. The constriction and the increased vasomotion 
were observed without a significant change for at least 20 
minutes after removal of ET-1 from the superfusate (data 
not shown). Note that ET-1-induced a transient [Ca²⁺], 
increase and a sustained vasoconstriction while exposure 
to 10 mmol/l Ca²⁺ induced an increase in [Ca²⁺], and a 
parallel vasoconstriction.

We tested the potency of different Rho-kinase inhibitors 
reversing ET-1-induced constriction. Figure 1B shows an 
original recording of an ET-1-induced constriction which 
is antagonized by increasing concentrations of fasudil. 
Fasudil mediated vasodilation were induced without sig-
nificantly altering [Ca²⁺],-levels. The Rho-kinase inhibi-
tors Y-27632, fasudil and hydroxy-fasudil reversed ET-1-
induced constriction (10 nmol/L) in a dose-dependent 
manner (Figure 1C). The IC₅₀ for Y-27632-, fasudil- and 
hydroxy-fasudil-mediated reversion of constriction was 3 
µmol/L (pIC₅₀ = 5.50 ± 0.31; n = 6), 15 µmol/L (pIC₅₀ = 
4.71 ± 0.13; n = 8; Figure 1D), fasudil (3 µmol/L) pre-
vented the ET-1-induced increase in the Ca²⁺ sensitivity 
(17 ± 3 versus -16 ± 2 µm/Ca²⁺, n = 8, Figure 1E). Taken 
together, these observations demonstrate that ET-1-
induced constriction in the SMA is maintained by a Rho-
kinase-mediated increase of the Ca²⁺ sensitivity of the 
contractile apparatus, which can be effectively reversed by 
Rho-kinase inhibition.

**Exogenous, cell-permeable cAMP (dbcAMP) reverses ET-
induced constriction and Ca²⁺ sensitization**

DbcAMP induced dose-dependant decreases in [Ca²⁺], 
and reversal of constriction induced by 1 nmol/L ET-1
with an EC50 of 1 mmol/L and 0.3 µmol/L (pEC50 = 2.97 ± 0.09 and 6.49 ± 0.07, n = 8, Fig. 2A and 2B), respectively. Note that dbcAMP-induced decreases in [Ca2+]i were less pronounced than those induced by removal of Ca2+ from the extracellular solution although dilations were comparable (Fig. 2A). This observation suggests that the dilatory effect of cAMP is at least in part due to a decrease of the Ca2+ sensitivity of the contractile apparatus. Consistent with this interpretation is the apparent rightward shift of the dose-response curve of dbcAMP for change in [Ca2+]i (Fig. 2B). If cAMP and ET-1 have opposing effects on the Ca2+ sensitivity, it should be possible to prevent the ET-1-induced increase in the Ca2+ sensitivity with dbcAMP. Indeed, 10 µmol/L dbcAMP prevented the increase in the Ca2+ sensitivity induced by 100 pmol/L ET-1 (-29 ± 4 versus -27 ± 3 µm/Ca2+, n = 7; Figure 2C). These observations support the hypothesis that cAMP and Rho-kinase can interact as functional antagonists at the level of the Ca2+ sensitivity of the contractile apparatus.

**Discussion**

The primary observation of the present study is that the ET-1-induced SMA vasoconstriction is reversed by the Rho-kinase inhibitors Y-27632, fasudil and hydroxy-fasudil and by the cAMP analogue dbcAMP. All four agents decreased VSMC contractile apparatus Ca2+ sensitivity.

In general, ET-1-induced constriction has been found to be elicited by different Ca2+ mobilizing mechanisms, including Ca2+ release from intracellular Ca2+ stores via a phospholipase C mediated activation of IP3-receptors and activation of L-type and non-selective Ca2+ channels [20-22]. Ca2+ mobilization has been considered to be the main mechanism of ET-1-induced constriction. In contrast, according to our previous results, ET-1-induced Ca2+ mobilization in the SMA appears to play a minor role [17]. The major mechanism of ET-1-induced constriction is an increase in the Ca2+ sensitivity of the contractile apparatus [9].

The increase in the Ca2+ sensitivity appears to be mediated by a Rho-kinase dependent inactivation of MLCP. This hypothesis is supported by two observations. First, inhibition of Rho-kinase with the selective Rho-kinase inhibitor Y-27632 abolished the ET-1-induced increase in the Ca2+ sensitivity. Y-27632 at concentrations of up to 10 µmol/L has been shown to be a selective Rho-kinase inhibitor [23-25]. Second, inhibition of Rho-kinase with the selective Rho-kinase inhibitors fasudil and its functional metabolite hydroxy-fasudil also reversed ET-1-induced constriction and Ca2+ sensitization of the contractile apparatus. These inhibitors have also been shown to be selective Rho-kinase inhibitors up to 20 µmol/L [24,26,27]. Since
Y-27632 and the fasudil derivatives are structurally unique, but were observed to have similar functional effects, the concern of non-specific effects of the inhibitors can be minimized.

It has been shown that the Rho-kinase-dependent inhibition of the MLCP results from phosphorylation of the myosin-binding subunit (MBS) of the enzyme [28]. All Rho-kinase inhibitors employed in the present study reversed ET-1-induced constriction, with a clinically relevant EC_{50} range below the level reported to cause systemic side effects (especially hypotension). This possibly indicates that basal Rho-kinase activity is rather low under normal conditions [23,29]. Thus, an up-regulation of Rho-kinase expression/activity under pathophysiological conditions (hypertension, cerebral and coronary vasospasm) would impart Rho-kinase inhibitors with pharmacological relevance [29].

We show that cAMP is a potent vasodilating second messenger in the SMA, acting by mechanisms which decrease [Ca^{2+}] and Ca^{2+} sensitivity. Although cAMP reduces intracellular Ca^{2+} levels, the present data demonstrate that the main pathway targets the Ca^{2+} sensitivity of the contractile apparatus. This interpretation is consistent with findings obtained in other preparations such as permeabilized intestinal and bronchial smooth muscle. In these studies the authors also could show that cAMP mediates a Ca^{2+} desensitization of the contractile apparatus [30,31]. cAMP seems to be the main second messenger of CGRP-induced Ca^{2+} desensitization and vasodilation in the SMA [18]. The data supports our hypothesis that the reversal of ET-1-induced constriction is not limited to inhibition of ET-1-related mechanisms (e.g., Rho-kinase signalling) and that ET-1-independent mechanisms can be targeted pharmacologically to reverse ET-1-mediated constriction. Clinical relevance arises from the possibility of modulating pharmacologically VSMC cAMP concentrations.

Conclusion

Although the sudden loss of hearing causes substantial distress and pronounced long-term effects in affected individuals, adequate strategies to clinically treat the disorder are lacking. One subgroup of SSHL is believed to arise from SMA vasospasm(s) which ultimately lead to ischemic stroke of the inner ear [32]. The targeting of two distinct signalling mechanisms, Rho-kinase and cAMP, were both effective in reversing SMA constriction. Of note, two of the agents employed in the present study (fasudil and hydroxy-fasudil) are currently used in the clinical setting and were found to be effective at concentrations below the threshold of systemic side effects [8,33]. Thus, this study presents two novel, clinically relevant approaches for the treatment of SSHL. We therefore propose that clinical investigation into the use of these agents for SSHL treatment is warranted.

Competing interests

The author(s) declare that they have no competing interests.

Authors’ contributions

EQS conducted all of the experiments and was involved in all aspects of data analysis and manuscript preparation. PW assisted with all facets of this study, assisting with data analysis and manuscript preparation. PW also provided laboratory space, equipment and financial support. WA provided financial support and made substantial contributions to conception and design of the present study.

All authors have been involved in drafting the manuscript and revising it critically for important intellectual content and given final approval of the version to be published.

Acknowledgements

The support by Research Grant RO1-DCO4280 from the National Institute on Deafness and Other Communication Disorders, National Institutes of Health is gratefully acknowledged. The authors thank Dr. Steffen-Sebastian Bolz and Dr. Darcy Lidingon for critically reviewing this manuscript and for giving important suggestions for improvement.

References

1. Hartshorne DJ: Biochemistry of the Contractile Process in Smooth Muscle. In Physiology of the Gastrointestinal Tract Edited by: Johnson LR. New York: Raven Press; 1987:423-482.
2. Somlyo AP, Somlyo AV. Ca^{2+} Sensitivity of Smooth Muscle and Nonmuscle Myosin II: Modulated by G Proteins, Kinases, and Myosin Phosphatase. Physiol Rev 2003, 83:1325-1358.
3. Kimura K, Ito M, Amano M, Chihiara K, Fukata Y, Nakaoku M, Yamamori B, Fang J, Nakano T, Oikawa K, Inwamu A, Kaibuchi K. Regulation of myosin phosphatase by Rho and Rho-associated kinase (Rho-kinase) [see comments]. Science 1996, 273:245-248.
4. Sato M, Tani E, Fujikawa H, Kaibuchi K. Involvement of Rho-kinase-mediated phosphorylation of myosin light chain in enhancement of cerebral vasospasm. Circ Res 2000, 87:195-200.
5. Fassbender K, Hodapp B, Rosso S, Bertsch T, Schmeck J, Schutt S, Fritzinger M, Horn P, Vajkoczy P, Wendel-Wellner M, Ragoschke A, Kuehl S, Brunner J, Schurrer L, Schmiedeck P, Hennerici M. Endothelin-1 in subarachnoid hemorrhage: An acute-phase reactant produced by cerebrospinal fluid leukocytes. Stroke 2000, 31:2971-2975.
6. Kandabashi T, Shimokawa H, Miyata K, Kunihiro I, Kawano Y, Fukata Y, Higo T, Egashira K, Takahashi S, Kaibuchi K, Takeshita A. Inhibition of Myosin Phosphatase by Upregulated Rho-Kinase Plays a Key Role for Coronary Artery Spasm in a Porcine Model With Interleukin-1 (beta). Circulation 2000, 101:1319-1323.
7. Shimokawa H. Rho-kinase as a Novel Therapeutic Target in Treatment of Cardiovascular Diseases. J Cardiovasc Pharmacol 2002, 39:319-327.
8. Masumoto A, Mohri M, Shimokawa H, Uraiki K, Utsui M, Takeshita A. Suppression of Coronary Artery Spasm by the Rho-Kinase Inhibitor Fasudil in Patients With Vasospastic Angina. Circulation 2002, 105:1545-1547.
9. Scherer EQ, Herzog M, Wangemann P. Endothelin-1-Induced Vasospasms of Spiral Modiolar Artery Are Mediated by Rho-Kinase-Induced Ca^{2+} Sensitization of Contractile Apparatus and Reversed by Calcitonin Gene-Related Peptide. Stroke 2002, 33:2965-2971.
10. Levin ER. Endothelins. N Engl J Med 1995, 333:356-363.
11. Haynes WG. Endothelins as regulators of vascular tone in man. Clin Lab (Coli): 1995, 88:509-517.
12. Rakugi H, Tabuchi Y, Nakamura M, Nagano M, Higashimori K, Mikami H, Oghara T, Suzuki N: Evidence for endothelin-1 release from resistance vessels of rats in response to hypoxia. Biochem Biophys Res Commun 1990, 169:973-977.
13. Xie H, Bevan JA: Oxidized low-density lipoprotein enhances myogenic tone in the rabbit posterior cerebral artery through the release of endothelin-1. Stroke 1999, 30:2423-2429.
14. Chow M, Dumont AS, Kassell NF: Endothelin receptor antagonists and cerebral vasospasm: an update. Neurosurgery 2002, 51:1331-1341.
15. Lan C, Das D, Wlosokowicz A, Vollrath B: Endothelin-1 modulates hemoglobin-mediated signaling in cerebrovascular smooth muscle via RhoA/Rho kinase and protein kinase C. Am J Physiol Heart Circ Physiol 2004, 286:H165-H173.
16. Suzuki Y, Tabuchi Y, Kimura K: Mechanism of endothelin I production in the cochlea of rats. ORL J Otorhinolaryngol Relat Spec 2001, 63:6-11.
17. Scherer EQ, Wonneberger K, Wangemann P: Differential desensitization of Ca2+ mobilization and vasoreactivity in ETA receptors in the gerbil spiral modiolar artery. J Membr Biol 2001, 182:35-191.
18. Herzog M, Scherer EQ, Albrecht B, Rorabaugh B, Scofield MA, Wangemann P: cGRP Receptors in the Gerbil Spiral Modiolar Artery Mediate a Sustained Vasodilation via a Transient cAMP-mediated Ca2+-decrease. J Membr Biol 2002, 189:225-236.
19. Wangemann P, Cohn ES, Gruber DD, Gratton MA: Ca2+-dependence and nifedipine-sensitivity of vascular tone and contractility in the isolated superfused spiral modiolar artery in vitro. Hear Res 1998, 118:90-100.
20. Goto K, Kasuya Y, Masaki N, Takawa Y, Kurihara H, Ishikawa T, Kimura S, Yanagisawa M, Masaki T: Endothelin activates the dihydropridine-sensitive, voltage-dependent Ca2+ channel in vascular smooth muscle. Proc Natl Acad Sci USA 1989, 86:3915-3918.
21. Enoki T, Miwa S, Sakamoto A, Minowa T, Komuro T, Kobayashi S, Ninomiya H, Masaki T: Functional coupling of ETA receptor with Ca2+-impermeable nonselective cation channel in mouse fibroblasts and rabbit aortic smooth-muscle cells. J Cardiovasc Pharmacol 1995, 26(Suppl 3):S258-S261.
22. Guibert C, Beech DJ: Positive and negative coupling of the endothelin ETA receptor to Ca2+-impermeable channels in rabbit cerebral cortex arteries. J Physiol (Lond) 1999, 514:843-856.
23. Uehata M, Ise S, Nishimura J, Hirano K, Kanaide H, Takeshita A: Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature 1997, 390:990-994.
24. Davies SP, Reddy H, Caivano M, Cohen P: Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J 2000, 351:95-105.
25. Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M, Narumiya S: Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. Mol Pharmacol 2000, 57:976-983.
26. Shimokawa H, Seto M, Katsumata N, Amano M, Kozai T, Yamawaki T, Kuwata K, Kandabashi T,乙shii G, Ikeda I, Asano T, Kaibuchi K, Takeshita A: Rho-kinase-mediated pathway induces enhanced myosin light chain phosphorylations in a swine model of coronary artery spasm. Cardiovase Res 1999, 43:1029-1039.
27. Nakamura K, Nishimura J, Hirano K, Ibayashi S, Fujishima M, Kanaide H: Hydroxyfasudil, an active metabolite of fasudil hydrochloride, relaxes the rabbit basilar artery by disinhibition of myosin light chain phosphatase. J Cereb Blood Flow Metab 2001, 21:875-883.
28. Kimura K, Ito M, Amano M, Chihara K, Fukata Y, Nakafuku M, Yamamori B, Feng J, Nakano T, Okawa K, Iwamatsu A, Kaibuchi K: Regulation of myosin phosphorylation by Rho and Rho-associated kinase (Rho-kinase). Science 1996, 273:245-248.
29. Mukai Y, Shimokawa H, Matoba T, Kandabashi T, Satoh S, Hiroki J, Kaibuchi K, Takeshita A: Involvement of Rho-kinase in hypertensive vascular disease: a novel therapeutic target in hypertension. FASEB J 2001, 15:1062-1064.
30. Bonnevier J, Fassler R, Somlyo AP, Somlyo AV, Arner A: Modulation of Ca2+ Sensitivity by Cyclic Nucleotides in Smooth Muscle from Protein Kinase G-deficient Mice. J Biol Chem 2004, 279:5146-5151.
31. Ise S, Nishimura J, Hirano K, Kanaide H: Theophylline attenuates Ca2+ sensitivity and modulates BK channels in porcine tracheal smooth muscle. Br J Pharmacol 2003, 140:939-947.
32. Lee H, Sohn SI, Jung DK, Cho YW, Lim JG, Yi SD, Lee SR, Sohn CH, Baloh RW: Sudden Deafness and Anterior Inferior Cerebellar Artery Infarction. Stroke 2002, 33:2807-2812.
33. Shibuya M, Suzuki Y, Sugita K, Saito I, Sasaki T, Takakura K, Nagata I, Kikuchi H, Takehara T, Hidaka H: Effect of AT877 on cerebral vasospasm after aneurysmal subarachnoid hemorrhage. Results of a prospective placebo-controlled double-blind trial. J Neurosurg 1992, 76:571-577.

Pre-publication history
The pre-publication history for this paper can be accessed here:

http://www.biomedcentral.com/1472-6815/5/10/prepub